73870-22-1

Usage

Uses

Used in Organic Synthesis:
Triphenyl-(2-pyridinylmethyl)-phosphoniumbromide is utilized as a phase transfer catalyst, which is instrumental in organic synthesis. Its ability to move reactants between different phases allows for smoother and more efficient reactions, particularly in processes that involve the transfer of ions or molecules from one phase to another.
Used in the Preparation of Other Organic Compounds:
In addition to its role as a catalyst, Triphenyl-(2-pyridinylmethyl)-phosphoniumbromide also serves as a reactant in the synthesis of other organic compounds. Its unique structure and reactivity make it a valuable component in the creation of new molecules with specific properties and applications.
Used in Pharmaceutical Industry:
Although not explicitly mentioned in the provided materials, given its role in organic synthesis and the preparation of other compounds, it is plausible that Triphenyl-(2-pyridinylmethyl)-phosphoniumbromide could be used in the pharmaceutical industry for the development of new drugs or drug delivery systems, where its phase transfer capabilities could be particularly advantageous.
Used in Chemical Research:
In the realm of chemical research, Triphenyl-(2-pyridinylmethyl)-phosphoniumbromide may be employed to study phase transfer phenomena and to develop new methodologies for chemical reactions. Its unique properties could provide insights into the behavior of reactants in different phases and contribute to the advancement of synthetic chemistry.

Upstream product

• 55401-97-3 2-(Bromomethyl)pyridine 
• 603-35-0 triphenylphosphine 
• 31106-82-8 2-(bromomethyl)pyridine hydrobromide 
• 109-06-8 α-picoline 

Downstream Products

• 886230-75-7 (Ε)-6-nitro-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)indazole 
• 1352049-10-5 1,1,1-trifluoro-3-pyridin-2-yl-3-(triphenylphosphoranylidene)acetone 
• 1352049-14-9 2-(1-(4-fluorobenzyl)-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)pyridine 
• 1352049-16-1 2-(1-(4-fluorobenzyl)-4-(trifluoromethyl)-1H-1,2,3-triazol-5-yl)pyridine 
• 926933-88-2 4-(4-pyridin-2-ylmethylene-piperidin-1-yl)-benzoic acid 

Relevant academic research and scientific papers

CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS

Compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to depression, major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder), cancers and eye conditions: wherein R1, , R3, and L are as defined herein.

Substituted dienes prepared from betulinic acid – Synthesis, cytotoxicity, mechanism of action, and pharmacological parameters

A set of new substituted dienes were synthesized from betulinic acid by its oxidation to 30-oxobetulinic acid followed by the Wittig reaction. Cytotoxicity of all compounds was tested in vitro in eight cancer cell lines and two noncancer fibroblasts. Almost all dienes were more cytotoxic than betulinic acid. Compounds 4.22, 4.30, 4.33, 4.39 had IC50 below 5 μmol/L; 4.22 and 4.39 were selected for studies of the mechanism of action. Cell cycle analysis revealed an increase in the number of apoptotic cells at 5 × IC50 concentration, where activation of irreversible changes leading to cell death can be expected. Both 4.22 and 4.39 led to the accumulation of cells in the G0/G1 phase with partial inhibition of DNA/RNA synthesis at 1 × IC50 and almost complete inhibition at 5 × IC50. Interestingly, compound 4.39 at 5 × IC50 caused the accumulation of cells in the S phase. Higher concentrations of tested drugs probably inhibit more off-targets than lower concentrations. Mechanisms disrupting cellular metabolism can induce the accumulation of cells in the S phase. Both compounds 4.22 and 4.39 trigger selective apoptosis in cancer cells via intrinsic pathway, which we have demonstrated by changes in the expression of the crucial apoptosis-related protein. Pharmacological parameters of derivative 4.22 were superior to 4.39, therefore 4.22 was the finally selected candidate for the development of anticancer drug.

FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Design, synthesis, in vitro cytotoxicity evaluation and structure-activity relationship of Goniothalamin analogs

A series of six/five member (E/Z)-Goniothalamin analogs were synthesized from commercially available (3,4-dihydro-2H-pyran-2-yl)methanol/5- (hydroxymethyl)dihydrofuran-2(3H)-one in three steps with good to moderate overall yields and their cytotoxicity against lymphoblastic leukemic T cell line (Jurkat E6.1) have been evaluated. Among the synthesized analogs, (Z)-Goniothalamin appeared to be the most active in cytotoxicity (IC 50 = 12 μM). Structure-activity relationship study indicates that introducing substituent in phenyl ring or replacing phenyl ring by pyridine/naphthalene, or decreasing the ring size of lactones (from six to five member) do not increase the cytotoxicity.

Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL

Overexpression of the antiapototic proteins Bcl-2 and Bcl-xL provides a common mechanism through which cancer cells gain a survival advantage and become resistant to conventional chemotherapy. Inhibition of these prosurvival proteins is an attractive strategy for cancer therapy. We recently described the discovery of a selective Bcl-xL antagonist that potentiates the antitumor activity of chemotherapy and radiation. Here we describe the use of structure-guided design to exploit a deep hydrophobic binding pocket on the surface of these proteins to develop the first dual, subnanomolar inhibitors of Bcl-xL and Bcl-2. This study culminated in the identification of 2, which exhibited EC50 values of 8 nM and 30 nM in Bcl-2 and Bcl-xL dependent cells, respectively. Compound 2 demonstrated single agent efficacy against human follicular lymphoma cell lines that overexpress Bcl-2, and efficacy in a murine xenograft model of lymphoma when given both as a single agent and in combination with etoposide.

Synthesis of the fused heterobicycles 5-pyridin-2-yl-thieno[3,2-b]pyridine, 6-pyridin-2-yl-thieno[2,3-b]pyridine and 6-pyridin-2-yl-thieno[3,2-c]pyridine

Three new pyridyl thienopyridines, 5-pyridin-2-yl-thieno[3,2-b]pyridine, 6-pyridin-2-yl-thieno[2,3-b]pyridine and 6-pyridin-2-yl-thieno[3,2-c]pyridine, have been synthesized, each through a different synthetic sequence. Overall yields ranged from 8% to 32%. Georg Thieme Verlag Stuttgart.

Irreversible photoisomerization behavior of 2-stilbazole ? covalently bound to porphyrin

Irreversible cis-to-trans photoisomerization behavior was observed for a stilbazole-porphyrin (1), and its zinc complex (2). trans-1 and trans-2 did not isomerize to the corresponding cis-isomer under irradiation with UV light, although stilbazoles readily undergo the trans-to-cis isomerization upon UV irradiation. In contrast, cis-to-trans photoisomerization was observed for both cis-1 and cis-2; the isomerization of cis-stilbazole readily proceeds by visible light irradiation via complexation with metalloporphyrins.

Two Step Redox Systems, XXVII. - Vinylogous Bipyridyls and Biquinolyls; Syntheses and UV/VIS-Spectra

The vinylogous 2,2'-, 2,4'- and 4,4'-bipyridyls 1(n=2,3), 2(n=2) and 3(n=2,3) together with the corresponding 2,2'-, 2,4'- and 4,4'-biquinolyls 4(n=2,3), 5(n=2) and 6(n=2,3) are synthesized, partly by different routes.Their UV/VIS spectra are described.